Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | POLQ | O75417 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21765854 | 0.89 | KMT2A (0.43) | KMT2APOLQALDH1A1TSHRNPC1 | |
| SCHEMBL1760632 | 0.84 | KMT2A (0.58) | KMT2APOLQALDH1A1NPC1RAB9A | |
| SCHEMBL9675188 | 0.84 | POLQ (0.50) | KMT2APOLQALDH1A1TSHRNPC1 | |
| SCHEMBL3399855 | 0.83 | TP53 (0.65) | KMT2APOLQALDH1A1TSHRMEN1 | |
| SCHEMBL5601309 | 0.83 | KMT2A (0.56) | KMT2APOLQALDH1A1MEN1CYP3A4 | |
| SCHEMBL7830345 | 0.83 | KMT2A (0.56) | KMT2APOLQALDH1A1MEN1CYP3A4 | |
| SCHEMBL98627 | 0.81 | KMT2A (0.54) | KMT2APOLQALDH1A1MEN1CYP3A4 | |
| SCHEMBL307215 | 0.81 | KMT2A (0.54) | KMT2APOLQALDH1A1MEN1CYP3A4 | |
| SCHEMBL1507876 | 0.81 | ALDH1A1 (0.64) | KMT2APOLQALDH1A1NPC1RAB9A | |
| SCHEMBL2189058 | 0.81 | KMT2A (0.59) | KMT2APOLQALDH1A1MEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005007094-A2 | ASTHMA AND ALLERGIC INFLAMMATION MODULATORS | TULARIK INC. (US) | 2005-01-27 | — | — | WO | claimed |
| CN-119317626-A | Pyrrolidone derivatives as inhibitors of NF- κb-induced kinase | 詹森药业有限公司 | 2025-01-14 | — | — | CN | disclosed |
| WO-2023224963-A1 | DUAL-ACTING ANGIOTENSIN AND ENDOTHELIN RECEPTOR ANTAGONISTS | ARIA PHARMACEUTICALS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230288610-A1 | WAVELENGTH SELECTIVE ABSORPTION FILTER AND DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2023-09-14 | — | — | US | disclosed |
| WO-2023172669-A2 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | OHIO STATE INNOVATION FOUNDATION (US) | 2023-09-14 | — | — | WO | disclosed |
| US-20230242514-A1 | BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2023-08-03 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| CN-113264844-B | Method for preparing aryl amide compound by catalyzing carbonylation of aryl tertiary amine without metal catalytic system | 宿州学院 | 2023-05-02 | — | — | CN | disclosed |
| EP-4125872-A1 | SUBSTITUTED AZOLE DIONE COMPOUNDS WITH ANTIVIRAL ACTIVITY | Stemline Therapeutics Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| US-6967196-B1 | Sulfonamide compounds and uses thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-22 | — | — | US | disclosed |
| EP-0623614-B1 | 4-Aryl-4-hydroxy-tetrahydropyrans and 3-aryl-3-hydroxy-tetrahydrofurans as 5-lipoxygenase inhibitors | ZENECA LTD (GB) | 1998-02-25 | — | — | EP | disclosed |
| EP-0790235-A1 | Diaryl alkane derivatives containing an alicyclic group, their preparation and their therapeutic and prophylactic uses | SANKYO COMPANY LIMITED (JP) | 1997-08-20 | — | — | EP | disclosed |
| EP-0558366-B1 | Process of making a rigid multi-layer preform | COOK COMPOSITES & POLYMERS (US) | 1996-09-25 | — | — | EP | disclosed |
| EP-0623614-A1 | 4-Aryl-4-hydroxy-tetrahydropyrans and 3-aryl-3-hydroxy-tetrahydrofurans as 5-lipoxygenase inhibitors | ZENECA LIMITED (GB) | 1994-11-09 | — | — | EP | disclosed |
| EP-0558366-A1 | Process of making a rigid multi-layer preform | COOK COMPOSITES AND POLYMERS (US) | 1993-09-01 | — | — | EP | disclosed |
| WO-1989007593-A1 | THERAPEUTIC AGENTS | THE BOOTS COMPANY PLC (GB) | 1989-08-24 | — | — | WO | disclosed |
| US-4766242-A | Synthesis of substituted aryl sulfides | HOECHST CELANESE CORPORATION (US) | 1988-08-23 | — | — | US | disclosed |
| EP-0252482-A2 | 7-Acyloxy-6-aminoacyloxypolyoxylabdanes, process for their preparation and their use as medicine | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-01-13 | — | — | EP | disclosed |
| EP-0217372-A2 | Polyoxygenated labdane derivatives, process for their preparation and their use as medicaments | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | KMT2A 1669/4885POLQ 3680/4885ALDH1A1 2019/4885 |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, BRCA1 | KMT2A 927/4885POLQ 119/4885ALDH1A1 2600/4885 |
| US-20230242514-A1 | BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, NR1I2 | KMT2A 4270/4885POLQ 4593/4885ALDH1A1 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.